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Reperfusion treatment in acute myocardial  
infarction in elderly patients
Frans Van de Werf
Department of Cardiovascular Sciences, KU Leuven, Belgium
A b s t r a c t
In this paper the current knowledge of reperfusion therapy in elderly patients with an ST-segment elevation acute myocardial 
infarction (STEMI) is summarised. Placebo-controlled trials of fibrinolytic agents, direct comparative trials of fibrinolytic agents 
and antithrombotic co-therapies, and randomised trials of primary percutaneous coronary intervention (PCI) versus fibrinolytic 
therapy as well as registries are briefly reviewed, focusing on the impact of age. The benefit and risk of a combined pharma-
cological and mechanical approach is presented. Important differences between a “facilitated PCI” and a “pharmaco-invasive 
strategy”, particularly in older STEMI patients, are highlighted. It will become clear at the end of this review that the knowledge 
about the benefit and risk of reperfusion therapy in the elderly is still incomplete and that more clinical trials in the elderly 
are needed. Practical recommendations for elderly patients with STEMI based on the current knowledge have been provided.
Key words: ST-segment elevation myocardial infarction, fibrinolysis, primary percutaneous coronary intervention, elderly
Kardiol Pol 2018; 76, 5: 830–837
INTRODUCTION
It is well-known that, especially in developed countries, the 
relative proportion of elderly patients with acute coronary 
syndromes is constantly increasing. In this regard it is amazing 
how little data we have on the optimal reperfusion treatment 
and outcomes of elderly patients who experience ST-segment 
elevation acute myocardial infarction (STEMI). Important 
questions have to be addressed but, unfortunately, answers 
are not available for all of them.
IS REPERFUSION WITH FIBRINOLYTIC AGENTS 
LIVE-SAVING IN THE ELDERLY?
The discussion of whether reperfusion (with fibrinolytic 
agents) is live-saving in STEMI patients aged 75 years or 
older started with the publication of the meta-analysis by the 
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group in 
Lancet in 1994 (Fig. 1) [1]. In this meta-analysis of randomised, 
placebo-controlled trials the effect of fibrinolytic therapy on 
35-day mortality in this age group was not significant (24.3% 
in subjects with fibrinolytic therapy vs. 25.3% in subjects 
without this therapy). However, a subsequent re-analysis of 
the results of this database in which elderly (aged 75 years or 
older), admitted with STEMI or new (or presumed to be new) 
left branch bundle block within 12 h of the symptom onset, 
were analysed, showed a significant 15% reduction of 35-day 
mortality with lytic therapy (Fig. 2). Registry data published 
around that time were also controversial. A Medicare analysis 
of 7864 patients ranging between 65 and 86 years of age 
raised concerns about the appropriateness of using fibrinolysis 
in the elderly after observing no survival benefit in patients 
above 75 years of age [2]. The apparent excess in mortality 
observed in this registry was probably due to a negative se-
lection bias, i.e. fitter elderly patients might have been more 
amenable to percutaneous coronary intervention (PCI), and 
a substantial portion of elderly patients receiving fibrinolytic 
therapy had one or more contraindications. Another obser-
vational study showed that of 719 elderly STEMI patients 
eligible for fibrinolytic therapy, only 63% actually received 
it, while 27% of patients with an absolute contraindication 
nevertheless received this therapy [3]. Such observational data 
underscore the complexity of interpreting outcomes given 
their confounding nature but were certainly not helpful in 
convincing cardiologists to give fibrinolytic therapy to elderly 
STEMI patients. By contrast, in another much larger analysis of 
37,983 Medicare patients above 65 years of age, fibrinolytic 
therapy resulted in a reduction in one-year mortality that was 
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comparable to primary PCI [4]. Similarly, in a Swedish registry, 
a propensity-adjusted analysis also demonstrated a significant 
improvement in survival in patients over the age of 74 years [5]. 
It is also important to realise that patients with prior stroke have 
often been included in registries and even clinical trials [6]. 
The apparent hazard conferred by fibrinolytic therapy in 
this context has been insufficiently addressed to date and 
has contributed — in the author’s view — to an unbalanced 
assessment of the role of fibrinolysis as a treatment option 
for the elderly.
It was hoped that fibrin-specific agents such as tissue-type 
plasminogen activator (tPA, alteplase) would not only be 
more effective but also safer because of the local action on 
the fibrin clot and the absence of a plasma lytic state. This is 
unfortunately not the case. In all studies with fibrin-selective 
agents there was an excess of intracranial haemorrhages when 
compared with streptokinase, a non-fibrin specific agent. 
However, because of a greater effectiveness for clot lysis (and 
thus for reperfusion) the “net clinical benefit” favoured the 
fibrin-specific agents. This was most clearly demonstrated in 
the large Global Utilisation of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries (GUSTO-1) 
trial with accelerated infusion of alteplase performed in more 
than 40,000 STEMI patients [7]. Different variants of alteplase 
have been developed subsequently with the aim of increasing 
the fibrin-specificity of the agent and decreasing the plasma 
clearance of the molecule so that the agent could be given as 
a bolus. Tenecteplase, developed by Genentech Inc. (South 
San Francisco, CA, USA), is the most successful alteplase vari-
ant. It can be given as a single bolus and is more fibrin-specific 
than alteplase. In different large-scale comparative studies 
it became clear that the higher the fibrin-specificity of an 
agent, the lower the risk of non-intracranial bleedings (tenec-
teplase < alteplase > < streptokinase). The early phase trials 
assessing the efficacy and safety of single-bolus tenecteplase 
used fixed, not weight-adjusted, doses of the agent. Several 
subsequent patency and pharmacokinetic analyses from these 
trials examined the relationship between body-weight, dose, 
and benefit versus risk. With increasing weight (i.e. lower 
weight-adjusted dose), the rate of successful reperfusion ap-
peared to decrease incrementally. Above a weight-adjusted 
dose of about 0.5 mg/kg, there was no improvement in 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow 
rates, whereas below this dose, patency rates decreased 
significantly. The opposite was seen for major bleeding com-
plications. In the end, a 10-kg tiered, weight-adapted dose 
of tenecteplase was chosen for the phase 3 programme [8]. 
In the double-blind Assessment of the Safety and Efficacy of 
Figure 1. Age-related outcomes in placebo-controlled trials with fibrinolytic agents included in the analysis of Fibrinolytic Therapy 
Trialists’ (FTT) collaboration [1]; CI — confidence interval; NS — not significant; SD — standard deviation
Figure 2. Re-analysis of outcomes in the elderly from the  
Fibrinolytic Therapy Trialists’ (FTT) data base; LBBB — left  
bundle branch block; STEMI — ST-segment elevation  
myocardial infarction
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a New Thrombolytic (ASSENT-2) trial, 16,949 patients were 
randomised to the single bolus weight-adapted tenecteplase 
or weight-adjusted front-loaded alteplase [9]. Specifically 
designed as an equivalence trial, this study showed that tenect-
eplase and alteplase were equivalent for 30-day mortality. The 
two treatments did not differ significantly in any subgroup 
analysis, including the elderly, except for lower 30-day mor-
tality with tenecteplase in patients treated 4 h after symptom 
onset. Although the overall rates of intracranial haemorrhage 
were almost identical for tenecteplase (0.93%) and alteplase 
(0.94%), it was noted that female patients, the elderly 
(> 75 years), and patients weighing less than 67 kg tended 
to have lower rates of intracranial bleeding after tenecteplase 
treatment. Nevertheless, in spite of a weight-adjusted dose 
for both fibrinolytic agents, more intracranial bleedings were 
observed in patients with lower body weight and among the 
elderly. There was a clear age-related increase in intracranial 
haemorrhage rate: 0.75% in patients between 63 and 67 years 
old, 1.57% in patients between 68 and 72 years old, 2.03% in 
patients between 73 and 78 years old, and 2.22% in patients 
above 78 years old. Tenecteplase tended to have fewer intrac-
ranial haemorrhages (1.72%) than alteplase (2.62%) in patients 
older than 75 years, but this difference was not significant.
WHICH ANTITHROMBOTIC CO-THERAPY  
SHOULD BE GIVEN WITH FIBRINOLYTIC AGENTS?
More potent inhibition of platelet aggregation by clopidogrel, 
on top of aspirin, further reduces the risk of early throm-
botic complications (reocclusion). In the large ClOpidogrel 
and Metoprolol in Myocardial Infarction Trial (COMMIT), 
45,852 Chinese patients with possible myocardial infarction 
(including 11,934 above the age of 70 years) were randomised 
to placebo or 75 mg of clopidogrel daily, without a loading 
dose [10]. Clopidogrel was found to be associated with sig-
nificant reduction in the risk of the two co-primary endpoints, 
in-hospital death, reinfarction or stroke (–9%), and all-cause 
mortality (–7%). This benefit was consistent across all age 
groups, including the 55% of patients treated with fibrinolysis 
(not all patients had STEMI). The incidence of intracranial and 
major non-intracranial bleeding was low, and not different 
between the two treatment arms. Importantly, there was no 
excess of intracranial or major bleeding in the elderly or in 
fibrinolytic-treated patients. In the Clopidogrel as Adjunctive 
Reperfusion Therapy–Thrombolysis in Myocardial Infarction 
(CLARITY–TIMI 28) trial, which compared clopidogrel (300 mg 
loading dose and maintenance dose of 75 mg/day) with place-
bo in fibrinolytic-treated STEMI patients, no individuals above 
75 years of age were studied [11]. No excess in intracranial 
haemorrhage was found in patients in the clopidogrel arm. 
Whereas a loading dose of 300 mg of clopidogrel was given 
upfront with tenecteplase, followed by a daily dose of 75 mg 
in the Strategic Reperfusion Early after Myocardial Infarction 
(STREAM) study (see pharmaco-invasive strategy below), no 
loading dose was given in patients ≥ 75 years because of 
a lack of safety data, both before and after halving the dose 
of tenecteplase during the trial [12]. However, it remains 
uncertain whether an upfront loading dose of clopidogrel is 
necessary in the elderly now that half-dose tenecteplase ap-
pears to yield a favourable risk/benefit ratio in these patients 
(see below). In the author’s view, the addition of an upfront 
loading dose of a P2Y12 inhibitor in elderly STEMI patients 
receiving a pharmaco-invasive reperfusion requires further 
study. It is important to note that the newer P2Y12 antago-
nists (ticagrelor, prasugrel, cangrelor) have not been studied 
together with fibrinolytic agents. In the recently published 
Ticagrelor in Patients With ST Elevation Myocardial Infarction 
Treated With Pharmacological Thrombolysis (TREAT) study in 
patients < 76 years, ticagrelor was given on average 11.4 h 
after administration of the lytic and did not result in a benefit 
over clopidogrel on 30-day outcomes [13]. There was a sig-
nificantly higher incidence of minor bleeding complications 
up to 30 days in the patients allocated to ticagrelor.
Fibrin-specific fibrinolytics require additional anticoagula-
tion, and the optimal anticoagulant and dosing for elderly pa-
tients has long been a matter of debate. An age-adjusted dose 
of enoxaparin was evaluated in the Enoxaparin and Throm-
bolysis Reperfusion for Acute Myocardial Infarction Treatment 
(ExTRACT)-TIMI 25 study: no bolus and 0.75 mg/kg twice daily 
in patients ≥ 75 years, versus the standard 30 mg intravenous 
loading bolus followed by 1 mg/kg bid in younger patients [14]. 
Age-adjusted enoxaparin increased the risk of major bleeding 
but not the risk of intracranial haemorrhage after fibrinolytic 
therapy, as compared to unfractionated heparin, while still 
reducing the risk of ischaemic complications. The increased 
risk of non-intracranial bleeding complications was offset by 
a significant reduction of ischaemic events, however, result-
ing in an 18% improvement in net clinical benefit compared 
with unfractionated heparin. Since ExTRACT, age-adjusted 
enoxaparin has been the recommended anticoagulant ac-
companying fibrin-specific fibrinolytics. 
In conclusion, it is now well-accepted and clearly recom-
mended in all guidelines that reperfusion therapy with fibrino-
lytic agents is effective in elderly patients with STEMI admitted 
within 12 h of symptom onset. In the most recent European 
Society of Cardiology (ESC) guidelines, weight-adjusted single 
bolus tenecteplase together with enoxaparin (no intravenous 
bolus) and clopidogrel (no loading dose) is recommended 
as the preferred fibrinolytic treatment [15]. The question 
remains: which is the best reperfusion therapy in the elderly 
(fibrinolysis or primary PCI), and does one size fit all?
WHICH REPERFUSION THERAPY  
WORKS BEST IN THE ELDERLY?
Only a limited number of trials have compared fibrinolytic 
therapy with primary PCI in elderly patients in a prospec-
tive randomised manner. The oldest and, surprisingly, also 
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the largest study is the Primary Angioplasty in Myocardial 
Infarction (SENIOR-PAMI) trial. In this study 483 patients 
above the age of 70 years were randomised to lytic therapy 
or primary PCI. Randomisation was stratified according to 
age category: from 70 to 80 and > 80 years of age. Data 
were available from 481 patients. In the first age category 
there was a numerically lower incidence of death or death 
plus stroke at 30 days in the primary PCI group. When 
re-infarction was added to the combined endpoint the 
difference became significant (7.7% vs. 17%, p = 0.0093). 
Surprisingly, in patients older than 80 years this combined 
endpoint was identical in the two groups (22%) and the rates 
of death and death plus stroke were numerically higher in 
the primary PCI group (Fig. 3). This study was presented in 
2005 at a Transcatheter Cardiovascular Therapeutics meeting 
but, to the author’s knowledge, it has never been published 
[16]. A later, prospective randomised study, the TRIANA trial, 
had to be stopped prematurely because of lack of recruit-
ment [17]. Data on 266 STEMI patients above the age of 
75 years were analysed. The mean age was 81 years. The 
primary endpoint was the composite of all-cause death, 
re-infraction, or disabling stroke at 30 days. This was reached 
in 18.9% of the patients allocated to primary PCI and in 
25.4% of those allocated to fibrinolytic therapy (odds ratio 
0.69 [0.38–1.2], p = 0.21). No differences in total mortality 
were observed between the two treatments.
Regarding observational studies, an important paper 
analysing and summarising the results of the different trials 
was published in 2005 [18]. Overall, the data from that analy-
sis suggested a better outcome with primary PCI than with 
thrombolytic therapy (Fig. 4). In conclusion, there is evidence 
that primary PCI is better than lytic therapy also in the elderly, 
although convincing studies are lacking.
PRIMARY PCI FOR ALL ELDERLY  
STEMI PATIENTS?
The time delay from the ESC diagnosis of STEMI to the start of 
reperfusion by PCI is often underestimated for several reasons, 
especially in the elderly. Atypical presentation is an important 
reason why the diagnosis of STEMI is often delayed in elderly 
patients. On screening in an emergency department, the 
elderly with atypical symptoms are often considered as less 
urgent cases. When it comes to estimating the delay between 
diagnosis based on electrocardiogram (ECG) and PCI-mediat-
ed reperfusion, the recent ESC guidelines define “crossing the 
lesion with the guide wire” as “start of reperfusion”. As shown 
in Figure 5 there are many steps (time delays) to be taken into 
account besides the transport of a patient to a PCI hospital. 
These delays may explain the gap between estimated and 
real time delays. For example, in a large United States registry 
of 22,481 patients the median estimated inter-hospital drive 
time was 57 min (interquartile range, 36–88 min). When the 
estimated drive time exceeded 30 min, only 42.6% of transfer 
patients treated with primary PCI achieved the first door (of 
the community hospital)-to-balloon time within 120 min [19].
A PHARMACO-INVASIVE STRATEGY?
An important recent development has been the concept of 
a pharmaco-invasive strategy, the components of which are 
early fibrinolysis in conjunction with rescue PCI in patients 
with fibrinolytic failure and subsequent early angiography/PCI 
in those with lytic success. A key feature of this strategy is that 
Figure 3. Age-related outcomes of Senior PAMI comparing fibrinolytic therapy with primary percutaneous coronary intervention 
(PCI) in the elderly [16]; CVA — cardiovascular adverse events; reMI — re-infarction
www.kardiologiapolska.pl
Frans Van de Werf
834
Figure 4. Summary of registry data comparing fibrinolytic therapy with primary percutaneous coronary intervention (PCI) [18];  
TT — thrombolytic therapy. *In-hospital mortality; **for ideal patients; ***combined in-hospital mortality and stroke in patients 
with acute myocardial infarction without shock
Figure 5. Summary of changes made in the 2017 European Society of Cardiology STEMI guidelines [15]; abbreviations — see the 
original article [15]
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fibrinolytic therapy is given in the ambulance or the emergen-
cy department of the community hospital, and that the patient 
is then immediately transferred to the PCI hospital (without 
waiting for the result of the fibrinolytic treatment). On arrival at 
the PCI hospital (preferably a cath lab) a second ECG is taken, 
and when there is evidence of successful lysis (e.g. > 50% 
ST-segment resolution) no immediate coronary angiography is 
performed. The reason why the invasive procedure is delayed 
by at least 2 to 3 h is to avoid any possible pro-thrombotic 
effect of the lytic agent. In case of failed fibrinolysis rescue 
PCI must be performed immediately. It is very important 
that a so-called “facilitated PCI” is clearly differentiated from 
primary PCI. In a facilitated PCI strategy the decision to per-
form immediate PCI is made as soon as the diagnosis. Lytic 
therapy is given to mitigate the so-called PCI-related delay. 
The coronary angiography/PCI is performed immediately 
on arrival in the cath lab, regardless of the outcome of the 
preceding fibrinolytic therapy. As shown in multiple studies, 
facilitated PCI does not provide any benefit over primary 
PCI. The key study comparing a pharmaco-invasive strategy 
with standard primary PCI is the STREAM-1 study [12]. In this 
analysis of 1892 STEMI patients who could not be treated 
with primary PCI within 1 h of the first medical contact, the 
pharmaco-invasive strategy with tenecteplase, enoxaparin, 
and clopidogrel was at least as good as primary PCI for the 
primary endpoint of death, shock, congestive heart failure, or 
reinfarction at 30 days. However, after approximately one-fifth 
of the planned STREAM population had been enrolled, the 
tenecteplase bolus was halved in patients ≥ 75 years of age 
because of an excess of intracranial haemorrhages in this age 
group. Before reducing the dose of tenecteplase, three out 
of 42 (7.1%) lytic-treated elderly patients experienced an 
intracranial haemorrhage, and two of these were fatal. This 
change was induced by a successful strategy of half-dose 
tenecteplase followed by immediate transfer applied in STEMI 
patients presenting to rural hospitals in Minnesota [20]. In this 
prospective registry, all patients diagnosed with STEMI beyond 
60 miles from the PCI centre (n = 839, 160 ≥ 75 years) re-
ceived half-dose tenecteplase, in association with 600 mg of 
clopidogrel, irrespective of age. The strategy appeared to be 
both effective and safe: only two patients experienced an in-
tracranial bleeding, and the pre-PCI patency (TIMI grade 2/3) 
was an impressive 74%. After implementing the dose reduc-
tion in STREAM, not a single additional intracranial bleeding 
or stroke was observed in the subsequent 97 patients above 
the age of 75 years randomised into the pharmaco-invasive 
arm. The efficacy in reperfusion of half a bolus of tenecteplase 
in these elderly patients was assessed by evaluating the extent 
of ST-segment resolution ≥ 50% on post-treatment ECG at 
60 to 90 min, and was found to be similar before and after 
the amendment [20]. Similarly, the percentage of lytic-treated 
elderly patients requiring rescue PCI was comparable before 
versus after halving the dose (43% vs. 44%). In addition, the 
primary composite endpoint was numerically lower after 
Figure 6. Design of STREAM-2 trial [KU Leuven, Belgium]; angio — coronary angiography; CABG — coronary artery bypass  
grafting; ECG — electrocardiogram; ER — emergency room; STEMI — ST-segment elevation myocardial infarction; PCI —  
percutaneous coronary intervention; TIMI — Thrombolysis in Myocardial Infarction; TNK — tenecteplase
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the amendment (25% vs. 31% before). Taken together, these 
observations suggest that a half-dose bolus tenecteplase in 
association with the currently recommended anti-thrombotic 
concomitant therapy appears to be safer but is still efficacious 
for elderly patients. However, more definitive prospective data 
are required in an adequately powered randomised clinical 
trial. Such a study, STREAM-2, is currently ongoing and analyses 
elderly patients (≥ 70 years old) with STEMI, randomised within 
3 h of onset of symptoms. It aims to compare the efficacy and 
safety of two strategies, according to local standards: early 
fibrinolytic treatment with half-dose tenecteplase, additional 
antiplatelet therapy with aspirin and a loading dose of 300 mg 
of clopidogrel coupled with enoxaparin, followed by coronary 
angiography within 6 to 24 h or rescue coronary intervention, 
as required, and standard primary PCI with a P2Y12 antagonist 
and antithrombin treatment (Fig. 6).
CONCLUSIONS AND PRACTICAL  
RECOMMENDATIONS
Despite evidence that fibrinolytic therapy improves outcomes 
irrespective of age, many elderly STEMI patients remain un-
dertreated or subject to major delays to primary PCI, in part 
because of concerns about bleeding risk associated with this 
type of therapy. Curiously, while age-specific dose reductions 
have been made to concomitant antithrombotic drugs such 
as clopidogrel and enoxaparin, until recently no dose-adjust-
ments have been made in the case of the fibrinolytic agents in 
the elderly. In the pharmaco-invasive STREAM-1 trial, halving 
the bolus of tenecteplase for patients above 75 years of age 
because of an unacceptably high intracranial bleeding rate in 
the elderly receiving a full dose of tenecteplase (after including 
about 20% of the total population) was associated with a more 
favourable safety/efficacy profile. An ongoing STREAM-2 trial 
aims to assess whether a pharmaco-invasive strategy including 
half-dose tenecteplase, age- and weight-adjusted enoxaparin, 
and clopidogrel, followed by routine coronary angiography 
represents a safe and efficacious alternative reperfusion 
therapy for elderly patients. 
In the meantime, the following strategies should be rec-
ommended in patients ≥ 75 years old (based on the 2017 ESC 
STEMI guidelines) (Fig. 5) [15]:
 — primary PCI is recommended in all STEMI patients up 
to 12 h after onset of symptoms if crossing the wire of 
the culprit lesion can be performed within 120 min of 
the ECG diagnosis;
 — if the above is not possible, immediate fibrinolytic 
therapy should be given. The preferred pharmaco-
logical cocktail is half-dose of tenecteplase, enoxaparin 
0.75 mg/kg (no loading, max 75 mg), 75 mg clopidogrel 
(no bolus), plus 150 to 300 mg of aspirin. After admin-
istration, patients should be immediately transferred to 
the PCI hospital.
According to the guidelines, patients < 75 years old 
should be treated with full-dose tenecteplase, an additional 
intravenous bolus of enoxaparin, and a loading dose of 
300 mg of clopidogrel. Obviously this 75-year cut-off age 
is artificial and does not take into account biological age 
and comorbidities. It is known that the bleeding risk in 
fibrinolytic therapy generally starts to increase around the 
age of 60 years. Giving frail STEMI patients between the age 
of 60 and 75 years a reduced dose of the fibrinolytic cock-
tail (as explained above) is worth considering, especially if 
a back-up option of a cath lab is available in case the ad-
ministered reduced dose of the fibrinolytic cocktail fails. In 
this regard, a recent pharmaco-invasive study (Early Routine 
Catheterisation After Alteplase Fibrinolysis Versus Primary 
PCI in Acute ST-Segment-Elevation Myocardial Infarction 
[EARLY-MYO]) in Chinese STEMI patients < 76 years of 
age supports this recommendation. This study showed 
favourable results with half-dose alteplase in comparison 
to standard primary PCI in STEMI patients who could not 
be treated with primary PCI within 1 h. No intracranial 
haemorrhages were observed, and there was even evi-
dence of better tissue reperfusion in those allocated to the 
pharmaco-invasive strategy [21]. 
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